Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X4P-001 + Pembrolizumab in Advanced Melanoma
NCT02823405Phase 1Completed
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Sep 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mavorixafor in melanoma, sponsored by X4 Pharmaceuticals, Inc. Primary endpoints: Incidence of Treatment-Emergent Adverse Events up to 13 weeks and Histology Characterization in Sequential Biopsies of Melanoma Lesions up to 13 weeks. Started Sep 2016; status: completed.
02
Drugs
mavorixafor
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02823405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02823405.